AbCellera BiologicsABCL
About: AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Employees: 596
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3.28% more ownership
Funds ownership: 38.56% [Q4 2024] → 41.84% (+3.28%) [Q1 2025]
13% less funds holding
Funds holding: 146 [Q4 2024] → 127 (-19) [Q1 2025]
17% less capital invested
Capital invested by funds: $334M [Q4 2024] → $279M (-$55.3M) [Q1 2025]
26% less call options, than puts
Call options by funds: $682K | Put options by funds: $927K
35% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 49
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Truist Securities Robyn Karnauskas | 213%upside $10 | Buy Maintained | 16 May 2025 |
Keybanc Scott Schoenhaus | 56%upside $5 | Overweight Maintained | 16 Apr 2025 |
Financial journalist opinion
Based on 3 articles about ABCL published over the past 30 days
